A Phase 3 interventional study of Cabazitaxel (XRP6258) and Prednisone (or Prednisolone) in Prostate Cancer, sponsored by Sanofi. Completed at 172 sites in 22 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-17.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.
Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one has the largest enrollment, is one of 5 that started in 2011, is one of 7 in phase 3, and was the 3rd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Case Comprehensive Cancer Center · Sites in United States
Ages 19+
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Fundacion Oncosur · Sites in Spain
Ages 18+ · Men only
Jina Pharmaceuticals Inc.
Ages 18+ · Men only
By country, each count listing its studies:
cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 7 · Phase 4 2
First in 2007; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,200 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 60 across the 46 interventional studies. Of the 29 that completed or were terminated, 14 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 46 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
34 studies in Prostatic Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 34 studies in Prostatic Neoplasms by Sanofi, this one is the 2nd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2011, is one of 10 in phase 3, and was the 23rd registered.
Sanofi’s Prostatic Neoplasms studies by the year they started, since 2001.
2 of the studies testing cabazitaxel in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06890832Jina Pharmaceuticals Inc.A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | 2026-12 |
| NCT06085729M.D. Anderson Cancer CenterPhase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | 2027-09-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, from their registry updates:
Among Sanofi’s 34 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objectives:
To compare efficacy of Cabazitaxel at 20 mg/m² and 25 mg/m² for:
Participants were treated until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles. All participants were followed when on study treatment and after completion of study treatment during follow up period until death or the study cutoff date, whichever came first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
I 01. Diagnosis of or cytologically proven prostate adenocarcinoma, that was resistant to hormone therapy and previously treated with a docetaxel-containing regimen.
I 02. Participant must had either measurable or non-. I 03. Received prior castration by orchiectomy and/or Luteinizing Hormone-Releasing Hormone (LH-RH) agonist with or without antiandrogen, antiandrogen withdrawal, monotherapy with estramustine, or other hormonal agents.
I 04. > 6 months. I 05. (ECOG) performance status (PS) 0 - 2 (i.e, participant must be ambulatory, capable of all self-care, and up and about more than 50% of waking hours).
I 06. Age ≥18 years (or country's legal age of majority if the legal age was > 18 years).
Exclusion criteria:
E 01. Previous treatment with mitoxantrone or cabazitaxel. E 02. Prior isotope therapy or radiotherapy to ≥30% of bone marrow. In case of prior isotope therapy 12 weeks must had elapsed prior to first study drug administration.
E 03. Adverse events (excluding alopecia and those listed in the specific exclusion criteria) from any prior anticancer therapy of grade >1(National Cancer Institute Common Terminology Criteria [] v4.03) at the time of randomization.
E 04. Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment in the study.
E 05. Prior . Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer were allowed, as well as any other cancer for which chemotherapy had been completed ≥ 5 years ago and from which the participant had been disease-free for ≥ 5 years.
E 06. Participation in another clinical trial and any concurrent treatment with any drug within 30 days prior to randomization.
E 07. Known brain or . E 08. Other concurrent serious illness or medical conditions. E 09. Uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension. History of congestive heart failure ( III or IV) or myocardial infarction within last 6 months was also not allowed.
E 10. Any severe acute or chronic medical condition which could impair the ability of the participant to participate to the study or to comply with the study procedures or interfere with interpretation of study results.
E 11. Absence of signed and dated Institutional Review Board (IRB)-approved participant form prior to enrollment into the study.
E 12. Participants with who did not agree to use accepted and effective method of during the study treatment period. The definition of "effective method of contraception" was based on the Investigator's judgment. Participant's Partners of (unless surgically sterile, post menopausal or for another reason had no chance of becoming pregnant) not protected by highly effective contraceptive method of birth control as defined for contraception in the Informed Consent Form and /or in a local protocol addendum.
E 13. History of to docetaxel, or polysorbate 80. E 14. Inadequate organ and bone marrow function. E 15. to the use of treatment. E 16. Symptomatic peripheral neuropathy grade > 2 (NCI CTCAE v.4.03).
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cabazitaxel 20 mg/m\^2 intravenous (IV) infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
Drug: Cabazitaxel (XRP6258) · Drug: Prednisone (or Prednisolone)
Cabazitaxel 25 mg/m\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
Drug: Cabazitaxel (XRP6258) · Drug: Prednisone (or Prednisolone)
Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous
Also known as: Jevtana®
Pharmaceutical form: Tablet Route of administration: Oral
Overall Survival (OS)
OS was defined as the time interval from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earlier of the last date the participant was known to be alive or the study cut-off date. The cut-off date for the final analysis of OS was the date when the 988th death had been observed. Analysis was performed by Kaplan-Meier method.
Time frame: From baseline up to death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Progression Free Survival (PFS)
PFS was evaluated from date of randomization to date of first documentation of any of the events: 1) Radiological tumor progression: as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1: at least a 20% increase in sum of diameters of target lesions (sum must also demonstrate an absolute increase of ≥5 mm) taking as reference the smallest sum while on study, appearance of one or more new lesions, or unequivocal progression of existing non target lesions, 2) Prostate Specific Antigen (PSA) progression: ≥25% increase over baseline/nadir value if baseline PSA ≥10 ng/mL; or 25% increase above the baseline level if baseline PSA \>0 ng/mL \& \<10 ng/mL; or post-baseline value of \>=2 ng/mL, if baseline PSA=0 ng/mL, 3) Pain progression: increase of ≥1 point in median Present Pain Intensity (PPI) from nadir or ≥25% increase in mean analgesic score (AS) from baseline score or requirement of local palliative radiotherapy, 4) Death. Analysis was performed by Kaplan-Meier method.
Time frame: From baseline up to tumor progression, PSA progression, pain progression, death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Time to Tumor Progression
Time to Tumor progression was defined as the first occurrence of radiological tumor progression according to RECIST 1.1. Radiological tumor progression was defined at least a 20% increase in sum of diameters of target lesions (sum must also demonstrate an absolute increase of ≥5 mm) taking as reference the smallest sum while on study, appearance of one or more new lesions, or unequivocal progression of existing non target-lesions. Analysis was performed by Kaplan-Meier method.
Time frame: From baseline up to tumor progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Percentage of Participants With Overall Objective Tumor Response
Overall objective tumor response was defined as either a partial response (PR) or complete response (CR) according to the RECIST 1.1 criteria, as assessed by the investigator. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From baseline up to DP or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Time to PSA Progression
Time to PSA progression was time interval between randomization \& first occurrence of PSA progression. PSA progression defined as: 1) PSA responders (\>50% decline from baseline PSA ≥10 ng/mL): increase of ≥25% (≥2 ng/mL) over nadir value, confirmed by second PSA ≥3 weeks later; 2) PSA non-responders (did not achieve \>50% decline from baseline PSA ≥10 ng/mL): increase of ≥25% (≥2 ng/mL) over baseline value, confirmed by second PSA ≥3 weeks later; 3) In participants not eligible for PSA response (baseline PSA \<10 ng/mL): (a) participants with baseline PSA \>0 ng/mL \& \<10 ng/mL: increase in PSA by 25% (≥2 ng/mL) above baseline level, confirmed by second PSA value ≥3 weeks apart; (b) participants with baseline value=0 ng/mL: post-baseline PSA value ≥2 ng/mL. Note (for 1-3): Rise in PSA in first 12 weeks was progression only if met definition above and was associated with other sign of DP or if it continued beyond 12 weeks. Analysis was performed by Kaplan-Meier method.
Time frame: From baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Percentage of Participants With PSA Response
PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.
Time frame: From baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Time to Pain Progression
Pain Progression was defined as an increase of ≥1 point in the median PPI from its nadir confirmed by a second assessment at least 3 weeks later or ≥25 % increase in the mean AS compared with the baseline score confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. AS was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.
Time frame: From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)
Percentage of Participants With Pain Response
Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in AS, or a ≥50% decrease from baseline mean AS without increase in the PPI score, maintained for 2 consecutive evaluations at least 3 weeks apart. Increases in pain during the first 12 weeks were ignored in determining pain response.
Time frame: From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of Health Related Quality of Life (HRQoL)
FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P TOI combines physical well-being, functional well-being, and prostate-specific concerns sub-scales for a total possible score range of 0 to 104, where higher values represent better HRQoL.
Time frame: Baseline, Day 1 of each Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 (each cycle 21-day); post-treatment follow up 1 (up to 12 weeks)
Change From Baseline in FACT-P:Total Score as a Measure of HRQoL
FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P Total Score sums all 5 sub-scales to give a score in the range of 0 to 156, where higher values represent better HRQoL.
Time frame: Baseline, Day 1 of each Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 (each cycle 21-day); post-treatment follow up 1 (up to 12 weeks)
Percentage of Participants With FACT-P Total Score Response
FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P Total Score sums all 5 sub-scales to give a score in the range of 0 to 156, where higher values represent better HRQoL. Responder of FACT-P was defined as at least one occurrence of 7-point improvement from baseline in FACT-P total score during treatment period.
Time frame: From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)
Time to Definitive Deterioration of Score by 10% From Baseline on FACT-P Sub-Scales
The time to definitive deterioration (10% decrease in score from baseline) was assessed for the individual sub-scales (Physical Well-Being; Social/Family Well-Being; Emotional Well-Being; Functional Well-Being; Prostate-Specific Concerns). Analysis was performed by Kaplan-Meier method.
Time frame: From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)
Time to Definitive Deterioration of ECOG PS Score From Baseline
The ECOG PS was used to evaluate participant's DP and the effect of the disease on the participant's activities of daily living. It ranges on the scale from 0-5 (0= normal activity; 1= symptoms but ambulatory; 2= in bed for \< 50 % of the time; 3= in bed for \> 50% of the time; 4= 100% bedridden; 5= dead). Time to definitive deterioration in ECOG PS score from baseline was defined as a change from 0, 1 to ≥2, or from 2 to ≥3. Analysis was performed by Kaplan-Meier method.
Time frame: From baseline until death or study cut-off date (maximum duration: 48 months)
Time to Definitive Weight Loss by 5% and 10% From Baseline
Time to definitive weight loss was defined as the time to first occurrence of ≥5% or ≥10% decrease in body weight from baseline. Analysis was performed by Kaplan-Meier method.
Time frame: From baseline until death or study cut-off date (maximum duration: 48 months)
Time to First Definitive Consumption of Narcotic Medication
Concomitant medications used were recorded for all participants, and time of first definitive consumption of narcotic medication (if it occurred) was determined. This measure summarizes the time from baseline to first definitive consumption of narcotic medication. Analysis was performed by Kaplan-Meier method.
Time frame: From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed or worsened or became serious during on-treatment period. On-treatment period: The time from the first dose of treatment to 30 days after the last dose of treatment (either Cabazitaxel or Prednisone). A serious adverse event: Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) version 4.03 (Grade 3 \[severe\] and Grade 4 \[life-threatening\]) was used in this study to grade clinical AEs.
Time frame: From first administration of study treatment until 30 days after the last administration of study treatment (Maximum duration: 48 months)
Plasma Clearance (CL) for Cabazitaxel
Blood samples for pharmacokinetic (PK) analysis were obtained from a subset of the study participants (approximately 150 participants/group, by protocol) according to a sparse sampling strategy.
Time frame: Day 1 of Cycle 1: 5 minutes before the end of infusion (EOI), 15 minutes, 1 to 4 hour, 6 to 24 hours, 48 to 168 hour after EOI
Plasma Steady State Volume of Distribution (Vss) for Cabazitaxel
Blood samples for PK analysis were obtained from a subset of the study participants (approximately 150 participants/group, by protocol) according to a sparse sampling strategy.
Time frame: Day 1 of Cycle 1: 5 minutes before the EOI, 15 minutes, 1 to 4 hour, 6 to 24 hours, 48 to 168 hour after EOI
The study was conducted at 172 centers in 22 countries. A total of 1463 participants were screened between 19 April 2011 and 18 November 2013. Out of 1463 participants, 1200 participants were enrolled in this study and 263 were not eligible to join the study.
| Milestone | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Started | 598 | 602 |
| Treated | 587 | 588 |
| Completed | 586 | 595 |
| Not completed | 12 | 7 |
| Withdrew: Lost to follow-up | 12 | 7 |
OS was defined as the time interval from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earlier of the last date the participant was known to be alive or the study cut-off date. The cut-off date for the final analysis of OS was the date when the 988th death had been observed. Analysis was performed by Kaplan-Meier method.
| months | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Overall Survival (OS) | 13.4 (12.19 to 14.88) | 14.5 (13.47 to 15.28) |
PFS was evaluated from date of randomization to date of first documentation of any of the events: 1) Radiological tumor progression: as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1: at least a 20% increase in sum of diameters of target lesions (sum must also demonstrate an absolute increase of ≥5 mm) taking as reference the smallest sum while on study, appearance of one or more new lesions, or unequivocal progression of existing non target lesions, 2) Prostate Specific Antigen (PSA) progression: ≥25% increase over baseline/nadir value if baseline PSA ≥10 ng/mL; or 25% increase above the baseline level if baseline PSA \>0 ng/mL \& \<10 ng/mL; or post-baseline value of \>=2 ng/mL, if baseline PSA=0 ng/mL, 3) Pain progression: increase of ≥1 point in median Present Pain Intensity (PPI) from nadir or ≥25% increase in mean analgesic score (AS) from baseline score or requirement of local palliative radiotherapy, 4) Death. Analysis was performed by Kaplan-Meier method.
| months | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Progression Free Survival (PFS) | 2.9 (2.79 to 3.45) | 3.5 (3.12 to 3.94) |
Time to Tumor progression was defined as the first occurrence of radiological tumor progression according to RECIST 1.1. Radiological tumor progression was defined at least a 20% increase in sum of diameters of target lesions (sum must also demonstrate an absolute increase of ≥5 mm) taking as reference the smallest sum while on study, appearance of one or more new lesions, or unequivocal progression of existing non target-lesions. Analysis was performed by Kaplan-Meier method.
| months | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Time to Tumor Progression | 9.0 (8.38 to 9.79) | 9.3 (8.61 to 9.92) |
Overall objective tumor response was defined as either a partial response (PR) or complete response (CR) according to the RECIST 1.1 criteria, as assessed by the investigator. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Percentage of Participants With Overall Objective Tumor Response | 18.5 (13.8 to 23.1) | 23.4 (18.2 to 28.6) |
Time to PSA progression was time interval between randomization \& first occurrence of PSA progression. PSA progression defined as: 1) PSA responders (\>50% decline from baseline PSA ≥10 ng/mL): increase of ≥25% (≥2 ng/mL) over nadir value, confirmed by second PSA ≥3 weeks later; 2) PSA non-responders (did not achieve \>50% decline from baseline PSA ≥10 ng/mL): increase of ≥25% (≥2 ng/mL) over baseline value, confirmed by second PSA ≥3 weeks later; 3) In participants not eligible for PSA response (baseline PSA \<10 ng/mL): (a) participants with baseline PSA \>0 ng/mL \& \<10 ng/mL: increase in PSA by 25% (≥2 ng/mL) above baseline level, confirmed by second PSA value ≥3 weeks apart; (b) participants with baseline value=0 ng/mL: post-baseline PSA value ≥2 ng/mL. Note (for 1-3): Rise in PSA in first 12 weeks was progression only if met definition above and was associated with other sign of DP or if it continued beyond 12 weeks. Analysis was performed by Kaplan-Meier method.
| months | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Time to PSA Progression | 5.7 (4.96 to 6.47) | 6.8 (6.11 to 7.46) |
PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.
| percentage of participants | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Percentage of Participants With PSA Response | 29.5 (25.6 to 33.3) | 42.9 (38.8 to 47.1) |
Pain Progression was defined as an increase of ≥1 point in the median PPI from its nadir confirmed by a second assessment at least 3 weeks later or ≥25 % increase in the mean AS compared with the baseline score confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. AS was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.
| months | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Time to Pain Progression | 6.2 (5.22 to 7.39) | 6.4 (5.55 to 7.26) |
Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in AS, or a ≥50% decrease from baseline mean AS without increase in the PPI score, maintained for 2 consecutive evaluations at least 3 weeks apart. Increases in pain during the first 12 weeks were ignored in determining pain response.
| percentage of participants | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Percentage of Participants With Pain Response | 34.7 (28.8 to 40.6) | 37.3 (31.7 to 42.9) |
FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P TOI combines physical well-being, functional well-being, and prostate-specific concerns sub-scales for a total possible score range of 0 to 104, where higher values represent better HRQoL.
| units on a scale | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Change from baseline at cycle 1 (n =521, 494) | 4.69 (2.95 to 6.44) | 5.08 (3.32 to 6.84) |
| Change from baseline at cycle 2 (n = 500, 494) | 4.4 (2.67 to 6.14) | 5.55 (3.81 to 7.3) |
| Change from baseline at cycle 3 (n =456, 451) | 3.75 (2 to 5.5) | 5.46 (3.7 to 7.23) |
| Change from baseline at cycle 4 (n =420, 415) | 2.57 (0.8 to 4.33) | 3.82 (2.04 to 5.6) |
| Change from baseline at cycle 5 (n =339, 361) | 1.78 (-0.03 to 3.59) | 3.06 (1.26 to 4.87) |
| Change from baseline at cycle 6 (n =275, 318) | 2.57 (0.72 to 4.43) | 2.03 (0.2 to 3.86) |
| Change from baseline at cycle 7 (n =225, 262) | 2.51 (0.6 to 4.42) | 2.73 (0.85 to 4.6) |
| Change from baseline at cycle 8 (n =196, 227) | 1.44 (-0.5 to 3.39) | 2.08 (0.16 to 3.99) |
| Change from baseline at cycle 9 (n =165, 172) | 0.94 (-1.06 to 2.94) | 1.46 (-0.55 to 3.46) |
| Change from baseline at cycle 10 (n =137, 141) | 0.02 (-2.05 to 2.1) | 1.31 (-0.76 to 3.39) |
| Change from baseline at Follow-up 1 (n =136, 152) | -2.27 (-4.35 to -0.19) | -1.16 (-3.21 to 0.88) |
FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P Total Score sums all 5 sub-scales to give a score in the range of 0 to 156, where higher values represent better HRQoL.
| units on a scale | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Change from baseline at cycle 1 (n =521, 495) | 5.6 (3.43 to 7.78) | 5.75 (3.55 to 7.95) |
| Change from baseline at cycle 2 (n = 502, 492) | 5.39 (3.23 to 7.55) | 6.23 (4.05 to 8.42) |
| Change from baseline at cycle 3 (n = 459, 452) | 4.39 (2.21 to 6.57) | 6.09 (3.89 to 8.3) |
| Change from baseline at cycle 4 (n = 421, 415) | 2.94 (0.73 to 5.14) | 4.2 (1.98 to 6.42) |
| Change from baseline at cycle 5 (n = 339, 365) | 1.79 (-0.46 to 4.04) | 3.33 (1.08 to 5.59) |
| Change from baseline at cycle 6 (n = 275, 320) | 2.57 (0.26 to 4.88) | 2.35 (0.06 to 4.64) |
| Change from baseline at cycle 7 (n = 229, 267) | 2.62 (0.25 to 4.99) | 2.72 (0.38 to 5.06) |
| Change from baseline at cycle 8 (n = 196, 226) | 1.35 (-1.08 to 3.78) | 1.98 (-0.42 to 4.37) |
| Change from baseline at cycle 9 (n = 164, 172) | 1.1 (-1.4 to 3.6) | 1 (-1.5 to 3.51) |
| Change from baseline at cycle 10 (n = 137, 141) | 0.02 (-2.57 to 2.61) | 1.33 (-1.26 to 3.93) |
| Change from baseline at Follow-up 1 (n = 137, 153) | -3.1 (-5.69 to -0.51) | -2.09 (-4.65 to 0.46) |
FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P Total Score sums all 5 sub-scales to give a score in the range of 0 to 156, where higher values represent better HRQoL. Responder of FACT-P was defined as at least one occurrence of 7-point improvement from baseline in FACT-P total score during treatment period.
| percentage of participants | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Percentage of Participants With FACT-P Total Score Response | 57.2 (53.0 to 61.4) | 59.4 (55.2 to 63.6) |
The time to definitive deterioration (10% decrease in score from baseline) was assessed for the individual sub-scales (Physical Well-Being; Social/Family Well-Being; Emotional Well-Being; Functional Well-Being; Prostate-Specific Concerns). Analysis was performed by Kaplan-Meier method.
| months | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Physical well-being | 6.6 (5.85 to 7.82) | 8.3 (7.16 to 8.74) |
| Social/family well-being | 10.8 (9.26 to 13.37) | 12.4 (8.97 to 13.83) |
| Emotional well-being | 9.7 (7.36 to 11.30) | 9.9 (8.54 to 12.52) |
| Functional well-being | 6.6 (5.55 to 7.43) | 6.7 (6.01 to 8.34) |
| Prostate specific concern | 8.7 (7.62 to 9.66) | 9.7 (8.77 to 10.87) |
The ECOG PS was used to evaluate participant's DP and the effect of the disease on the participant's activities of daily living. It ranges on the scale from 0-5 (0= normal activity; 1= symptoms but ambulatory; 2= in bed for \< 50 % of the time; 3= in bed for \> 50% of the time; 4= 100% bedridden; 5= dead). Time to definitive deterioration in ECOG PS score from baseline was defined as a change from 0, 1 to ≥2, or from 2 to ≥3. Analysis was performed by Kaplan-Meier method.
| months | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Time to Definitive Deterioration of ECOG PS Score From Baseline | 14.9 (11.43 to 23.59) | 14.1 (12.22 to 20.17) |
Time to definitive weight loss was defined as the time to first occurrence of ≥5% or ≥10% decrease in body weight from baseline. Analysis was performed by Kaplan-Meier method.
| months | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Weight Loss by 5% | 10.6 (9.26 to 13.17) | 11.1 (10.12 to 12.42) |
| Weight Loss by 10% | NA (12.65 to NA) | 20.3 (14.23 to NA) |
Concomitant medications used were recorded for all participants, and time of first definitive consumption of narcotic medication (if it occurred) was determined. This measure summarizes the time from baseline to first definitive consumption of narcotic medication. Analysis was performed by Kaplan-Meier method.
| months | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Time to First Definitive Consumption of Narcotic Medication | 2.2 (0.99 to 3.65) | 0.8 (0.30 to 2.20) |
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed or worsened or became serious during on-treatment period. On-treatment period: The time from the first dose of treatment to 30 days after the last dose of treatment (either Cabazitaxel or Prednisone). A serious adverse event: Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) version 4.03 (Grade 3 \[severe\] and Grade 4 \[life-threatening\]) was used in this study to grade clinical AEs.
| percentage of participants | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Any Grade TEAE | 91.2 | 93.9 |
| Any Grade 3-4 TEAE | 39.7 | 54.5 |
| Grade 3-4 TEAE excluding laboratory TEAE | 35.7 | 48.1 |
| Grade 3-4 TEAE excluding DP TEAEs | 39.0 | 53.9 |
| Grade 3-4 TEAE excluding laboratory and DP TEAEs | 35.0 | 47.4 |
| Any Serious TEAE | 30.5 | 43.2 |
| Any TEAE leading to permanent discontinuation | 16.4 | 19.5 |
Blood samples for pharmacokinetic (PK) analysis were obtained from a subset of the study participants (approximately 150 participants/group, by protocol) according to a sparse sampling strategy.
| Litre/hour | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Plasma Clearance (CL) for Cabazitaxel | 44.832 ± 15.075 | 49.662 ± 17.613 |
Blood samples for PK analysis were obtained from a subset of the study participants (approximately 150 participants/group, by protocol) according to a sparse sampling strategy.
| litre | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Plasma Steady State Volume of Distribution (Vss) for Cabazitaxel | 7381.46 ± 4488.72 | 7040.10 ± 5133.12 |
Collected over All AEs were collected from signature of the informed consent form up to the final visit (48 months) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabazitaxel 20 mg/m^2 | — | 177/580 (30.5%) | 450/580 (77.6%) |
| Cabazitaxel 25 mg/m^2 | — | 257/595 (43.2%) | 507/595 (85.2%) |
| Event | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 10/580 | 48/595 |
| NeutropeniaBlood and lymphatic system disorders | 3/580 | 27/595 |
| HaematuriaRenal and urinary disorders | 13/580 | 21/595 |
| Neutropenic infectionInfections and infestations | 8/580 | 17/595 |
| Urinary tract infectionInfections and infestations | 9/580 | 17/595 |
| Neutropenic sepsisInfections and infestations | 7/580 | 14/595 |
| AnaemiaBlood and lymphatic system disorders | 13/580 | 12/595 |
| DiarrhoeaGastrointestinal disorders | 5/580 | 13/595 |
| Disease progressionGeneral disorders | 8/580 | 13/595 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 7/580 | 8/595 |
| Event | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 175/580 | 231/595 |
| NauseaGastrointestinal disorders | 140/580 | 188/595 |
| FatigueGeneral disorders | 142/580 | 156/595 |
| AstheniaGeneral disorders | 88/580 | 114/595 |
| Decreased appetiteMetabolism and nutrition disorders | 74/580 | 108/595 |
| HaematuriaRenal and urinary disorders | 73/580 | 108/595 |
| ConstipationGastrointestinal disorders | 102/580 | 107/595 |
| VomitingGastrointestinal disorders | 78/580 | 105/595 |
| Back painMusculoskeletal and connective tissue disorders | 63/580 | 78/595 |
| DysgeusiaNervous system disorders | 41/580 | 63/595 |
| Age, Customized(participants) | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 | Total |
|---|---|---|---|
| <65 years | 182 | 180 | 362 |
| 65 to 74 years | 296 | 295 | 591 |
| ≥75 years | 120 | 127 | 247 |
| Sex: Female, Male(Participants) | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 598 | 602 | 1200 |
Showing the first 100 of 172 sites across 22 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2011, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cabazitaxel · Prednisone